Primevision Pharma Llp Profile
Key Indicators
- Obligation of Contribution ₹ 2.00 Cr
- Company Age 2 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.30 Cr
About Primevision Pharma Llp
Primevision Pharma Llp (PPL) is 2 Year, 11 Months old Limited Liability Partnership 01 February 2022. Its registered office is in Sangli, Maharashtra, India.
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 2.00 Cr as per MCA.
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN/FCRN
ABA-4515
- Incorporation Date
01 Feb 2022
- Date of Accounts and Solvency Statement
31 Mar 2023
- ROC Code
Roc-Pune
- Company Classification
Limited Liability Partnership
Industry
Who are the key members and board of directors at Primevision Pharma Llp?
Designated Partners (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niranjan Patil  | Designated Partner | 01-Feb-2022 | Current |
| Chetan Sankh | Designated Partner | 18-Mar-2022 | Current |
| Yogesh Mirji | Designated Partner | 18-Mar-2022 | Current |
| Rajendrakumar Dhanavade | Designated Partner | 18-Mar-2022 | Current |
| Vijay Magdum | Designated Partner | 18-Mar-2022 | Current |
| Ashishkumar Kore | Designated Partner | 01-Feb-2022 | Current |
Financial Performance of Primevision Pharma Llp.
Enhance accessibility to Primevision Pharma Llp's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Primevision Pharma Llp?
Unlock access to Primevision Pharma Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ns Unibiosys Medicare Private LimitedNiranjan Patil is a mutual person
- Eleazar Clinical Pharmacy Llp
Yogesh Mirji is a mutual person
Charges (Loans)
₹12.30 Cr
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 12.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Jul 2022 | Bank Of India | ₹12.30 Cr | Open |
How Many Employees Work at Primevision Pharma Llp?
Unlock and access historical data on people associated with Primevision Pharma Llp, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Primevision Pharma Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Primevision Pharma Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.